Follicular lymphoma and marginal zone lymphoma – associated burden of illness and health care utilization in Ontario
Client: IQVIA Solutions Canada Inc.
Project ID: P2020-074 / 2021 0970 236 000; P2021-091 / 2022 0970 236 001
Research Question/Objectives: Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) are subtypes of Non-Hodgkin’s lymphoma which is cancer of the lymphatic system, it is important to know the current burden of illness of FL/MZL in Canada because it ranks as the fifth most common cancer among men and fourth most common cancer among women in Canada . However, currently available data related to the burden of illness for Canadian FL/MZL patients are limited, making it difficult to accurately assess the impact of this patient population on the health care system. The proposed study also aims to summarize characteristics of the FL/MZL patient population.
Specifically, the primary research objectives of interest are:
- Identify FL/MZL patients and subgroups within the administrative data.
- Describe the characteristics of FL/MZL patients and subgroups in Ontario, including:
- demographic characteristics
- treatment patterns of attending physician visits, procedures, and medication use
- health care resource utilization (HCRU) and associated direct costs; and
- overall survival.
- To examine the health care resource utilization (HCRU) and direct healthcare costs (i.e., BOI) for relapsed FL/MZL patients in the relapsed setting
The secondary research objectives of interest are:
- To describe the demographic and clinical characteristics of relapsed FL/MZL patients.
- To determine the first line of therapy (LoT), second LoT for relapsed FL/MZL patients.
- To compare HCRU and direct healthcare costs of relapsed FL/MZL patients to general population controls.
- To determine third LoT and time to third LoT (i.e. time to next treatment (TTNT)) for relapsed FL/MZL patients.
- To estimate the overall survival of relapsed FL/MZL patients.
- To stratify HCRU, direct healthcare costs, TTNT (third LoT), overall survival outcomes by 1st and 2nd LoT sequences.
- February 2023